Abstract 2087
Background
The aim of this study was to determine the effect of e-mobile education on the quality of life of women diagnosed with breast cancer who received endocrine hormone therapy.
Methods
The study was conducted as a randomized controlled study between January and July 2018 in the Medical Oncology Outpatient Clinic of a state hospital in the province of Turkey.A total of 64 patients were included in the study according to the inclusion criteria of randomization, split into treatment (n = 31) and control group (n = 33).Data were collected using Patient Introductory Information Form, FACT-ES Quality of Life Scale and NCCN Distress Thermometer.The data were collected twice during the first week of the study and 12th week at the end of the study by face-to-face and/or telephone interviews.Treatment group patients were received information via mobile application for three months during which they were contacted in every 15 days; e-mobile training was provided, including information about breast cancer definition, treatment process, symptoms experienced during endocrine hormone therapy, adequate nutrition, regular physical activity and coping with stress.
Results
The mean total quality of life after e-mobile training to the treatment group was found to be significantly higher than the control group, and the mean distress score was lower than the control group (p < 0.05).For quality of life subscales of patients in the e-mobile training and treatment group; the scores of physical well-being, emotional well-being and endocrine symptoms were found to be significantly higher than the control group (p < 0.05).There was found no difference between the mean scores of social / family well-being subscale scores of the patients in the e-mobile training and treatment group and the control group.Treatment group reported that e-mobile training was “informative and useful a training” (87.1%).
Conclusions
As a result of the study, it has been concluded the quality of life of the patients increased when nurses use the e-mobile training and counseling in order to manage the disease process and symptoms of the women diagnosed with breast cancer and who are receiving endocrine hormone therapy with the help of the developing technologies and using the mobile technologies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3190 - GI101, a novel triple-targeting bispecific CD80-IgG4-IL2variant fusion protein, elicits synergistic anti-tumor effects in preclinical models
Presenter: Jae Chan Park
Session: Poster Display session 3
Resources:
Abstract
4062 - Phase 1b, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumors
Presenter: Julius Strauss
Session: Poster Display session 3
Resources:
Abstract
5777 - THOR-707, a novel not-alpha IL-2, promotes all key immune system anti-tumoral actions of IL-2 without eliciting vascular leak syndrome (VLS)
Presenter: Marcos Milla
Session: Poster Display session 3
Resources:
Abstract
5047 - A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells
Presenter: Alessandra Curioni
Session: Poster Display session 3
Resources:
Abstract
1679 - HPV16 E6-specific TCR-T armored with checkpoint blockade in the treatment of cervical cancer
Presenter: Paul Bryson
Session: Poster Display session 3
Resources:
Abstract
1133 - the Mutant Neoantigen Specific T Cell Is a Personalized Immunotherapy in Refractory Solid Tumor
Presenter: Qi Song
Session: Poster Display session 3
Resources:
Abstract
3338 - NY-ESO-1 and LAGE1A –an emerging target for cell therapies in solid tumours
Presenter: Ioanna Eleftheriadou
Session: Poster Display session 3
Resources:
Abstract
3089 - Targeting myeloid-derived suppressor cells and T cells: combination treatment with MTL-CEBPA and PD-1 antibody in a mouse syngeneic CT26 model
Presenter: Mikael Sodergren
Session: Poster Display session 3
Resources:
Abstract
5991 - Master Checkpoint Cbl-b Inhibition: Anti-tumor Efficacy in a Murine Colorectal Cancer Model Following siRNA-based Cell Therapy
Presenter: Kathrin Thell
Session: Poster Display session 3
Resources:
Abstract
5007 - Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
Presenter: Miren Zuazo
Session: Poster Display session 3
Resources:
Abstract